PDB33 PRESCRIBING TRENDS FOR COMBINATION PRODUCTS IN THE TREATMENT OF TYPE-II DIABETES  by Bilek, JC et al.
362 Abstracts
did not pay for their prescriptions were signiﬁcantly different 
(p < 0.05). The average anti-diabetic drug cost of the patients
who paid out-of-pocket was 643.38 Baht ($US 1 = 40Baht) and
their average total drug cost was 1853.12 Baht, while the average
anti-diabetic drug cost of the patients who did not pay for their
prescriptions was 437.91 Baht and their average total drug cost
was 990.94 Baht. In drug cost per day basis, the results showed
that the average anti-diabetic drug costs per day between two
patient groups were not signiﬁcantly different (p > 0.05).
However, their average total drug costs per day were signiﬁcantly
different (p < 0.05). The average total drug cost per day of the
patients who paid out-of-pocket was 26.76 Baht, while it was
17.56 Baht for the patients who did not pay for their prescrip-
tions. Linear regression results showed that the patient’s type of
payment signiﬁcantly inﬂuenced both anti-diabetic and total
drug cost per prescription and cost per day. CONCLUSIONS: A
signiﬁcant relationship between patient’s payment type and pre-
scription drug costs for diabetic patients was found. The patients
who paid out-of-pocket likely obtained more expensive pre-
scription drugs than did the patients who did not pay for their
prescriptions.
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OBJECTIVE: To examine prescribing trends of combination oral
hypoglycemic therapy for persons with Type-II diabetes using
prescription claims. METHODS: Prescribing trends were identi-
ﬁed for patients using combination oral hypoglycemic agents for
the treatment of diabetes during a three month period beginning
November, 2003–January, 2004. Persons were considered newly
treated with type II diabetes if there were no prescription claims
for insulin or oral diabetes agents during a three month period
prior to the ﬁrst prescription for a combination product. Trends
in patients already receiving oral hypoglycemic agents or insulin
were identiﬁed if combination therapy was added after mini-
mally three months of therapy or if oral hypoglycemic combi-
nation therapy was added to an existing treatment regimen
during the three-month observation period. Current recommen-
dations for use of combination therapy were compared to the
results of prescribing trends obtained from administrative data.
RESULTS: On average, approximately 661,811 persons were
identiﬁed with combination therapy on a monthly basis (211,922
in November, 2003; 227,981 in December, 2003; 221,908 in
January, 2004). Of these, on average approximately 130,708
received metformin/rosiglitazone, 491,380 received metformin/
glyburide, and 38,011 received metformin/glipizide. Several pre-
scribing trends were observed for these agents. Despite literature
to the contrary, the combination metformin/rosiglitazone was
prescribed as initial therapy for 19% of patients receiving pre-
scriptions for that product. Combination products were pre-
scribed as initial therapy for 11% to 19% of patients depending
on product. Almost 1% of patients received a combination
product plus two or more agents on a monthly basis. A small
number of patients received two combination products in their
daily regimen. CONCLUSION: Approximately one-ﬁfth of
patients receive initial oral hypoglycemic therapy outside of
current prescribing recommendations. The prescribing patterns
observed from this data suggest the need for treatment regimen
management and for plans to carefully study the economic
impact of multiple regimen treatments.
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Objective: To quantify the incidence and risk of needlestick
injury (NI) in nurses caring for patients with diabetes.
METHODS: Four hundred nurses caring for patients with dia-
betes in 381 hospitals throughout the United States reported data
on their experience with NI, focusing on those occurring within
the past year. If respondents experienced multiple NI during this
period, detailed data were collected on the most recent event.
RESULTS: Of the 400 nurses, 313 (78.3%) reported having ever
had a NI, 110 (27.5%) reported having had a NI within the last
twelve months, and 44 (40% of those 110) reported multiple NI.
Nearly two-thirds of these injuries (n = 73; 66.4%) were punc-
tures that drew blood, resulting in one case of contracted hepati-
tis C. The cumulative annual incidence of NI events was 448 NI
per 1000 nurses. Nurses reported the injury in adherence with
existing policies in 21.8% of cases. Disposable syringes were
involved in 88 (80%) of the events. In half of the injuries (n =
55), the needled device was equipped with a safety feature that
was ineffective, primarily because it was not fully activated (n =
47; 85.5%) or it malfunctioned (n = 2 to 5; 3.6% to 9.1%). NI
most commonly occurred while nurses were injecting insulin 
(n = 33; 30%). In the two weeks following their NI, 60.1% of
nurses were more afraid of needled devices than before the injury
and 41.8% felt anxious, depressed, or stressed. As a direct result
of the NI, nurses missed 77 days of work. CONCLUSIONS: This
study is the ﬁrst to show the relatively high risk both of NI and
of NI that draws blood among nurses injecting insulin with a
disposable syringe. Additionally, this study reveals signiﬁcant
post-NI emotional distress, suggests signiﬁcant under-reporting
of NI to hospital ofﬁcials, and demonstrates the need for a more
effective needle safety device.
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OBJECTIVE: For patients with type-1 diabetes, having a pre-
ferred insulin delivery system may lead to better compliance and
better clinical and patient-reported outcomes. The purpose of
this study was to assess the reliability and validity of the Insulin
Delivery System Questionnaire (IDSQ), an instrument developed
to measure overall insulin satisfaction and preference for an
insulin delivery system. METHODS: The IDSQ was adminis-
tered to 137 patients with type-1 diabetes at screening, baseline,
crossover, and endpoint of a randomized, noninferiority,
crossover trial designed to compare the glycemic control of
injectable vs. inhaled insulin. Psychometric analyses included
internal consistency (Cronbach’s alpha), factorial validity (prin-
cipal component analysis with Promax rotation), discriminant
validity (ANCOVA model with baseline score and other covari-
ates), and responsiveness (t-tests). RESULTS: Exploratory factor
analysis indicated that there were three factors accounting for
73% of the variance. All items loaded above >0.50 on either
Factor one, lifestyle impact; Factor two, ease of dosing; or Factor
three, satisfaction/preference with the exception of the “easy to
control my blood sugar” (BG) item. Cronbach’s alpha coefﬁ-
cients calculated for the factors were 0.93, 0.86, and 0.86,
